Not just a mouse study. They had the Phase II Hum
Post# of 149514
(Total Views: 547)
Posted On: 01/05/2025 6:19:14 PM
Not just a mouse study. They had the Phase II Human study which was more vague, but clearly showed reduction of both steatosis and fibrosis. I pointed that out in an earlier post today in reply to Ken Chowder where I referenced my post MASH Free For All.
The numbers were not so discernable and maybe Madrigal wanted to see it in a clearer format which SMC likely has provided.
This was in the shareholder's letter:
The bolded portion points to the fact that these results were impeccably proven already and ready for presentation. They waited until the results came back before even mentioning it to us in the shareholder letter.
Yes, they are still waiting on the 2nd preclinical murine study which should confirm the results of this initial preclinical murine study, but should also prove that leronlimab is capable of dissolving scar tissue and fibrosis regardless of its etiology. It shall also look at the effect of combining leronlimab with GLP-1 Agonist semaglutide which the 1st preclinical did not test.
If the results are excellent with the combination of leronlimab with semaglutide, then there may be an offer from Nova Nordisc incoming. However, if there is a licensing with Madrigal for MASH already in the making, then that would prevent Nova Nordisc from licensing leronlimab for MASH.
I'm thinking it may have been withdrawn from presentation due to discussions on the licensure of leronlimab for MASH likely with Madrigal.
The numbers were not so discernable and maybe Madrigal wanted to see it in a clearer format which SMC likely has provided.
This was in the shareholder's letter:
Quote:
"First, CytoDyn previously announced exciting results from an initial preclinical study with SMC Laboratories evaluating leronlimab in the treatment of a mouse model of MASH. The results from this preliminary study demonstrated that high dose leronlimab was significantly better at reversing liver fibrosis compared to an IgG 4 isotype control and demonstrated a trend toward better fibrosis reversal compared to Resmetirom. The final results from that study have now also demonstrated that leronlimab (both high and low dose) was significantly better than Resmetirom at reversal of fat deposition (steatosis) in the liver . These exciting findings have been submitted as a late breaker abstract to the MASH TAG conference and, if accepted, will be presented at the meeting in January."
The bolded portion points to the fact that these results were impeccably proven already and ready for presentation. They waited until the results came back before even mentioning it to us in the shareholder letter.
Yes, they are still waiting on the 2nd preclinical murine study which should confirm the results of this initial preclinical murine study, but should also prove that leronlimab is capable of dissolving scar tissue and fibrosis regardless of its etiology. It shall also look at the effect of combining leronlimab with GLP-1 Agonist semaglutide which the 1st preclinical did not test.
If the results are excellent with the combination of leronlimab with semaglutide, then there may be an offer from Nova Nordisc incoming. However, if there is a licensing with Madrigal for MASH already in the making, then that would prevent Nova Nordisc from licensing leronlimab for MASH.
I'm thinking it may have been withdrawn from presentation due to discussions on the licensure of leronlimab for MASH likely with Madrigal.
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼